Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasHodgkin LymphomaIndolent LymphomasT-Cell and NK-Cell NeoplasmsDiseaseAcute Lymphoblastic LeukaemiaChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, T-Cell Type, Anaplastic Large CellSubgroupICD10C81.-C82.-C82.7C82.9C83.1C83.3C83.7C84.4C91.0-C91.1-MeSHLymphoma, Mantle-CellLymphoma, T-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceIXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)ChemotherapyChemo-substanceCarboplatinCisplatinDexamethasoneGemcitabineRituximabChemo-substanceCarboplatinCisplatinDexamethasoneGemcitabineRituximabChemo-substanceCarboplatinCisplatinDexamethasoneGemcitabineRituximabChemo-substanceCarboplatinCisplatinDexamethasoneGemcitabineRituximabNo. Substances14 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateParacetamolPegfilgrastimPotassium chloridePrednisoloneNo. Substances3710Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationSecond lineTherapy phaseTherapy intentioncurativeRisksAnemia Hb below 8g/dlCardiotoxicityEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityInfectionsNeurotoxicityNeutropeniaPainThrombocytopenia below 50 000/µlThromboembolic EventVomiting only studiesPublicationAuthorCrump MDavies AGopal ADiseaserezidivierendes oder refraktäres Non-Hodgkin-Lymphom, ECOG 0-2Rezidivierte oder refraktäre, aggressive Lymphome, 2. Linie vor ASCT, ECOG 0-3OriginCancer Research UK Centre, University of Southampton, UK, SABRINA StudiePrincess Margaret Cancer Centre, Ontario, CanadaUniversity of Washington/Fred Hutchinson Cancer Research Center, Seattle, WAProtocols in Revision 3 protocols foundProtocols under revision.R-GDC - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Carboplatin 5, diffuse large B-non-Hodgkin Lymphoma (PID1681 V1.0)R-GDP - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Cisplatin 75, diffuse large B-non-Hodgkin Lymphoma (PID605 V1.4)Rituximab 1400, single dose subcutaneous (PID310 V2.0)
